Coalition for Epidemic Preparedness Innovation

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) said Thursday it’s observed a 100-percent antibody response in a phase I study for a Zika virus vaccine and a 92 percent antibody response in a phase I study for a MERS vaccine. The findings were presented at a Coalition for Epidemic Preparedness...